Hisamitsu Pharmaceutical Co., Inc.
HTSUY · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.01 | 7.48 | 0.00 |
| FCF Yield | 1.69% | 262.05% | 1.48% | 5.61% |
| EV / EBITDA | 5.45 | 0.07 | 12.48 | 0.10 |
| Quality | ||||
| ROIC | 4.88% | 440.34% | 257.49% | 1.71% |
| Gross Margin | 58.46% | 55.73% | 0.42% | 58.30% |
| Cash Conversion Ratio | 0.86 | 0.95 | 1.08 | 1.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -80.02% | 408.47% | 391.52% | -5.89% |
| Free Cash Flow Growth | -99.35% | 14,244.68% | -73.31% | 650.16% |
| Safety | ||||
| Net Debt / EBITDA | -3.20 | -0.01 | -2.95 | -0.04 |
| Interest Coverage | 821.57 | 731.50 | 103,753.33 | 4.19 |
| Efficiency | ||||
| Inventory Turnover | 2.86 | 443.41 | 2.98 | 3.15 |
| Cash Conversion Cycle | 158.18 | 0.93 | -7,228.69 | -5,888.33 |